单选题
Once-daily Pill Could Simplify HIV Treatment

Bristol-Myers Myers Squibb and Gilead Sciences have combined many HIV drugs into a single pill. Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and HIV/AIDS, for example, are all treated with (51) of drugs. But that can mean a lot of pills to take. It would be (52) if drug companies combined all the medicines into a single pill, taken just once a day.
Now, two companies say they have done that for people just (53) treatment for HIV, the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences. They have (54) a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them (55) the name of Sustiva. Gilead combined the (56) , Emtriva and Viread, into a single pill in two thousand four.
Combining drugs involves more than (57) issues. It also involves issues of competition (58) the drugs are made by different companies. The new once-daily pill is the result of (59) is described as the first joint venture agreement of its kind in the treatment of HIV.
In January the New England Journal of Medicine published a study of the new pill. Researchers compared its (60) to that of the widely used combination of Sustiva and Combivir. Combivir (61) two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed HIV levels in more patients and with (62) side effects. Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.
Glaxo Smith Kline reacted (63) the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.
The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries. They plan in the next few months to ask the United States Food and Drug Administration to (64) the new pill.
There are limits to who could take it because of the different drugs it contains. For example, (65) women are told not to take Sustiva because of the risk of birth disorders. Experts say more than forty million people around the world are living with HIV.

【正确答案】 C
【答案解析】本段中多次提到新药是由几种药合成在一起的，而原来则需要服用多种药物，本空白处四个选项中只有C项“组合物，结合体”是唯一恰当的选择。
【正确答案】 A
【答案解析】其实，本篇文章的标题就提示了本空白处正确的选项。
【正确答案】 A
【答案解析】这两家研制新药的公司让谁服用这些新药呢?只有A项“开始治疗”的人才有意义，其他三项均不再治疗，那有什么用呢?而且副词just(“即将，就要”)也起着帮助选择的作用。
【正确答案】 D
【答案解析】这两家公司将目前市售的三种药物合成一片，这只有是“开发，研发”(D项)，绝不能是“分析”、“检查”或“探查”。
【正确答案】 C
【答案解析】这几个介词中，只有under可以与name组合成短语under the name of(“以……名，名为……”)，其他选项在这里均不合适。
【正确答案】 D
【答案解析】上面提到两家公司已经开发出将多种药合成为单片的新药，Bristol-Myers公司已合成了一种，Gilead公司则于2004年将其他两种Emtriva和Viread合成为单片，这里既然列出了这两种药的名称，所以就必须用others。
【正确答案】 B
【答案解析】合成药物让人们首先想到的自然是“技术”问题，但不仅仅是技术问题，所以下句就提到竞争问题。
【正确答案】 A
【答案解析】竞争问题只有当不同药厂制同一类药品时才会出现，所以只有if才合适。
【正确答案】 C
【答案解析】本句中，the result of后面应该是一个宾语从句，空白处应该是宾语从句的主语，首先我们可以排除that和which，因为它们是用来连接定语从句的，其他两个，what=the thing(s) that, whatever=any thing that，两相比较，应该what恰当，因为这里指的是具体这一次，而不是泛指任何一次。
【正确答案】 D
【答案解析】研究人员对不同药物进行对比，自然是对比它们的疗效，其他三个选项的对比均毫无意义。
【正确答案】 B
【答案解析】四个选项中只有A和B可以考虑，exclude是“除外，排除”，与contain(“包含，含有”)正相反，因此，即使是不知道AZT和3TC可以治疗艾滋病也会选择B项，因为作者绝不会在没有说明AZT和3TC是什么样的药物的情况下就说不包含它们，如果这样就会让读者摸不着头脑。
【正确答案】 B
【答案解析】既然这种新药可抑制更多病人的HIV水平，副作用自然应该“更少”，这是使用新药前后的对比，故必须用比较级。
【正确答案】 C
【答案解析】react to(“对……作出反应”)是固定用法，其他选项均不对。
【正确答案】 D
【答案解析】从本句字面上看，他们打算在几个月内要求FDA干什么事情呢?而且是与新药有关，而FDA又是审批药品的机关，自然是approve(“批准”)了。
【正确答案】 D
【答案解析】本句后面已经提到，生育时可能有危险，那就只有孕妇(pregnant women)才涉及生育的问题了。